- About Us
- Nano-Social Network
- Nano Consulting
- My Account
NanoInk, Inc. announced today the appointment of Dean Hart, as its executive vice president of commercial operations.
"We are extremely pleased that Dean has joined the NanoInk team," said Jim Hussey, CEO of NanoInk. "His track record of success and commercial experience will be important to our plans for both Brand Protection and Dip Pen Nanolithography businesses."
Mr. Hart joins NanoInk from Vision Point of Sale, Inc., a leading point-of-sale equipment and services company located in Glenview, Ill., where he served as vice president of sales and marketing during the past two years.
Prior to joining Vision Point of Sale, Mr. Hart served as senior vice president of sales at Takeda Pharmaceuticals North America, Inc., a Deerfield, Ill.-based U.S. subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company. At Takeda, he was instrumental in the success of Takeda's flagship diabetes product and market leader, ACTOS®, and led the growth of Takeda's sales force to support the launch of two new products in the diabetes and sleep market.
Previously, Mr. Hart served as president of Sequest Technologies, where he successfully established a market presence for the Oakbrook, Ill. software company in the health care technology field.
Mr. Hart began his career in sales, marketing and sales management at Bristol-Myers Squibb where he held positions of increased responsibility up to and including his appointment to associate director regional operations in 1994. He became the national sales director for the U.S. subsidiary of the Japanese pharmaceutical company Eisai, Inc. in 1996. At Eisai, Mr. Hart built the sales organization and successfully launched Eisai's first product in the U.S. pharmaceutical marketplace, Aricept®, the most prescribed drug in the world for the treatment of Alzheimer's.
Mr. Hart holds a B.S. in Business Management from Indiana University and a Masters of Business Administration from the Kellogg School of Management at Northwestern University.
About NanoInk, Inc.
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the lifescience and semiconductor industries. With DPN, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair, and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, the University of Illinois at Urbana-Champaign, and the Georgia Institute of Technology.
For more information, please click here
Dresner Corporate Services
Dresner Corporate Services
Copyright © NanoInk, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017